ClinicalTrials.gg
CompletedNCT02981368OSPREYUpdated Aug 9, 2021Results posted

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

A Phase 2/3 interventional study of 18F-DCFPyL Injection and PET/CT imaging in Prostate Cancer, sponsored by Progenics Pharmaceuticals, Inc.. Completed at 10 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-09.

Sponsored by Progenics Pharmaceuticals, Inc. (part of Lantheus Holdings, Inc.) · Phase 2/3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
385
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing piflufolastat in Prostatic Neoplasms — 5 open to participants now, 10 under way, none of them phase 3. piflufolastat · Prostatic Neoplasms.

Enrollment
Largest of 24
385 · median 55
Started
2016
with 2 others
Phase 2/3
3 of 24
none open now
Registered
4th of 24
by date
Lead sponsor
2 of 24
Progenics Pharmaceuticals, Inc.

Among the 24 studies testing piflufolastat in Prostatic Neoplasms, this one has the largest enrollment, is one of 3 that started in 2016, is one of 3 in phase 2/3, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 24 studies testing piflufolastat in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About piflufolastat

piflufolastat: first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing piflufolastat in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B).

Cohort B is complete and no longer recruiting subjects.

03

Conditions studied

  • Prostate Cancer

Keywords

  • Diagnostic
  • Imaging
  • 2301
  • PET/CT
  • PyL
  • PSMA
  • radical prostatectomy
  • metastatic prostate cancer
  • recurrent prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed adenocarcinoma of the prostate.
  2. Subjects provide signed and confirm that they are able and willing to comply with all protocol requirements.

Cohort A Only:

  • At least high risk prostate cancer defined by NCCN Guidelines Version 3.2016 (clinical stage ≥T3a or PSA >20 ng/mL or Gleason score ≥8).
  • Scheduled or planned radical prostatectomy with PLND.

Cohort B Only: [Enrollment is complete; No longer recruiting subjects]

  • Radiologic evidence of local recurrence or new or progressive disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), whole-body bone scan (99m-Tc-MDP or Na-18F) within 4 weeks of enrollment.
  • If prior treatment with radiation or ablative therapy, evidence of recurrence outside the confines of prior treated site(s) is needed.
  • Scheduled or planned percutaneous of at least one amenable lesion.

Exclusion criteria

Exclusion Criteria:

  1. Subjects administered any high energy (>300 KeV) gamma-emitting radioisotope within five physical half-lives, or any IV iodinated contrast medium within 24 hours, or any high density oral contrast medium (oral water contrast is acceptable) within 5 days, prior to study drug injection.
  2. Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.

Cohort A Only:

  • Patients with prior androgen deprivation therapy or any agent or intervention

Cohort B Only: [Enrollment is Complete; No longer recruiting subjects]

  • Prior radiation or ablative therapy to intended site of , if within the prostate bed
  • Initiation of new therapy for recurrent and/or progressive disease since radiographic documentation of recurrence/progression.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
385 participants (actual)

Study arms

  • Experimental
    18F-DCFPyL Injection

    9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL

    Drug: 18F-DCFPyL Injection · Diagnostic Test: PET/CT imaging

Interventions

  • A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL

    Also known as: PyL

  • Diagnostic testPET/CT imaging

    PET/CT imaging will be acquired 1-2 hours post-PyL injection

06

What researchers measure

Primary outcomes

  1. Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)

    The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.

    Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.

  2. Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)

    The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.

    Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.

Secondary outcomes

  1. Shift From Baseline in Selected Hematology Laboratory Values at Follow-up (Safety Outcome Measure)

    Shifts from baseline to worst post-baseline visit for hematology laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.

    Time frame: From time of screening (baseline) until pre-surgery/biopsy (within 28 days post-study drug dosing).

  2. Shift From Baseline in Selected Clinical Chemistry Laboratory Values at Follow-up (Safety Outcome Measure)

    Shifts from baseline to worst post-baseline visit for clinical chemistry laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.

    Time frame: From time of screening (baseline) until pre-surgery/biopsy (within 28 days post-study drug dosing).

  3. Changes From Baseline in Electrocardiogram (ECG) Parameters (Safety Outcome Measure)

    Time frame: Changes in ECG pre-drug dosing and within 1-2 hours post-dosing

  4. Mean Changes From Baseline in Blood Pressure Post 18F-DCFPyL Dosing (Safety Outcome Measure)

    Time frame: Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.

  5. Mean Change From Baseline in Heart Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)

    Time frame: Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.

  6. Mean Change From Baseline in Respiration Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)

    Time frame: Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.

  7. Mean Change From Baseline in Temperature Post 18F-DCFPyL Dosing (Safety Outcome Measure)

    Time frame: Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.

  8. Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Prostate Cancer Within Sites of Metastasis or Local Recurrence Relative to Histopathology in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)

    Sensitivity (True Positive rate) measures the proportion of positives that are correctly identified (i.e., the proportion of those who have some condition (affected) who are correctly identified as having the condition).

    Time frame: Within 28 days of 18F-DCFPyL PET/CT imaging, conventional image-guided biopsy occurred.

  9. Comparison of Detection Rates for Lesion Counts By Location and Overall Between 18F-DCFPyL PET/CT and Conventional Imaging

    The number of lesions detected on imaging categorized as bone, visceral/soft tissue, lymph nodes, and the prostate gland will be determined by each of the central imaging core lab independent readers. The sum of lesions per participant per tissue type and overall will be computed for each participant based on each reader's lesion count. This will be calculated from the 18F-DCFPyL PET/CT scan results as well as the conventional imaging results.

    Time frame: Within 1-2 hours of 18F-DCFPyL dosing, a whole body PET/CT scan will be taken

  10. Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)

    Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.

    Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.

  11. Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)

    Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.

    Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.

  12. Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)

    Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.

    Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.

  13. Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)

    Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.

    Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.

  14. Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT Imaging to Predict Prostate Cancer Within Sites of Local Recurrence and Other Metastatic Lesions in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)

    Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL PET/CT image.

    Time frame: Within 28 days of 18F-DCFPyL PET/CT imaging, conventional image-guided biopsy will occur.

  15. Peak Plasma Concentration (Cmax) of 18F-DCFPyL in a Subset of Participants

    Time frame: Samples were collected at 0, 5, 15, 30, 60, 120, 240, 360, and 480 minutes after administration of 18F-DCFPyL.

  16. Area Under the Plasma Concentration Versus Time Curve (AUC) of 18F-DCFPyL in a Subset of Participants

    Time frame: Samples were collected at 0, 5, 15, 30, 60, 120, 240, 360, and 480 minutes after administration of 18F-DCFPyL.

07

Results

Posted Aug 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneHigh Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)
Started268117
Completed248102
Not completed2015

Outcome measures

PrimarySpecificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)

The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.

Time frame:
Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Reported as:
Number · percentage of participants
Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)
percentage of participantsHigh Risk Prostate Cancer (Cohort A)
Central Reader 197.9 (94.52 to 99.37)
Central Reader 298.9 (96.00 to 99.96)
Central Reader 396.3 (93.64 to 98.99)
PrimarySensitivity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)

The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.

Time frame:
Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Reported as:
Number · percentage of participants
Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)
percentage of participantsHigh Risk Prostate Cancer (Cohort A)
Central Reader 141.9 (29.65 to 54.22)
Central Reader 230.6 (19.17 to 42.12)
Central Reader 340.3 (28.11 to 52.53)
SecondaryShift From Baseline in Selected Hematology Laboratory Values at Follow-up (Safety Outcome Measure)

Shifts from baseline to worst post-baseline visit for hematology laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.

Time frame:
From time of screening (baseline) until pre-surgery/biopsy (within 28 days post-study drug dosing).
Reported as:
Count of participants · Participants
Shift From Baseline in Selected Hematology Laboratory Values at Follow-up (Safety Outcome Measure)
ParticipantsCohort A - Follow-up Value: LowCohort B - Follow-up Value: LowCohort A - Follow-up Value: NormalCohort B - Follow-up Value NormalCohort A - Follow-up Value: HighCohort B - Follow-up Value: HighCohort A - Follow-up Value: MissingCohort B - Follow-up Value: Missing
Hematocrit — Cohort A - Baseline Value: Low2601200020
Hematocrit — Cohort B - Baseline Value: Low0310600010
Hematocrit — Cohort A - Baseline Value: Normal290179010120
Hematocrit — Cohort B - Baseline Value: Normal0104700022
Hematocrit — Cohort A - Baseline Value: High00401000
Hematocrit — Cohort B - Baseline Value: High00000000
Hematocrit — Cohort A - Baseline Value: Missing00200000
Hematocrit — Cohort B - Baseline Value: Missing00000000
Hemoglobin — Cohort A - Baseline Value: Low160300020
Hemoglobin — Cohort B - Baseline Value: Low0330600013
Hemoglobin — Cohort A - Baseline Value: Normal180210010110
Hemoglobin — Cohort B - Baseline Value: Normal0204300018
Hemoglobin — Cohort A - Baseline Value: High00301010
Hemoglobin — Cohort B - Baseline Value: High00010001
Hemoglobin — Cohort A - Baseline Value: Missing00200000
Hemoglobin — Cohort B - Baseline Value: Missing00000000
Platelets — Cohort A - Baseline Value: Low120300010
Platelets — Cohort B - Baseline Value: Low09020003
Platelets — Cohort A - Baseline Value: Normal40230010130
Platelets — Cohort B - Baseline Value: Normal0307000029
Platelets — Cohort A - Baseline Value: High00200000
Platelets — Cohort B - Baseline Value: High00000100
Platelets — Cohort A - Baseline Value: Missing00200000
Platelets — Cohort B - Baseline Value: Missing00000000
Erythrocytes — Cohort A - Baseline Value: Low290800020
Erythrocytes — Cohort B - Baseline Value: Low0360100010
Erythrocytes — Cohort A - Baseline Value: Normal200194000110
Erythrocytes — Cohort B - Baseline Value: Normal0603900022
Erythrocytes — Cohort A - Baseline Value: High00100010
Erythrocytes — Cohort B - Baseline Value: High00020100
Erythrocytes — Cohort A - Baseline Value: Missing00200000
Erythrocytes — Cohort B - Baseline Value: Missing00000000
Leukocytes — Cohort A - Baseline Value: Low70300020
Leukocytes — Cohort B - Baseline Value: Low07010002
Leukocytes — Cohort A - Baseline Value: Normal402080180120
Leukocytes — Cohort B - Baseline Value: Normal0007101030
Leukocytes — Cohort A - Baseline Value: High00705000
Leukocytes — Cohort B - Baseline Value: High00030200
Leukocytes — Cohort A - Baseline Value: Missing00200000
Leukocytes — Cohort B - Baseline Value: Missing00000000
SecondaryShift From Baseline in Selected Clinical Chemistry Laboratory Values at Follow-up (Safety Outcome Measure)

Shifts from baseline to worst post-baseline visit for clinical chemistry laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.

Time frame:
From time of screening (baseline) until pre-surgery/biopsy (within 28 days post-study drug dosing).
Reported as:
Count of participants · Participants
Shift From Baseline in Selected Clinical Chemistry Laboratory Values at Follow-up (Safety Outcome Measure)
ParticipantsCohort A - Follow-up Value: LowCohort B - Follow-up Value: LowCohort A - Follow-up Value: NormalCohort B - Follow-up Value: NormalCohort A - Follow-up Value: HighCohort B - Follow-up Value: HighCohort A - Follow-up Value: MissingCohort B - Follow-up Value: Missing
Alkaline Phosphatase — Cohort A - Baseline Value: Low30300000
Alkaline Phosphatase — Cohort B - Baseline Value: Low00000004
Alkaline Phosphatase — Cohort A - Baseline Value: Normal50210000380
Alkaline Phosphatase — Cohort B - Baseline Value: Normal0006104035
Alkaline Phosphatase — Cohort A - Baseline Value: High00403000
Alkaline Phosphatase — Cohort B - Baseline Value: High00000904
Alkaline Phosphatase — Cohort A - Baseline Value: Missing00100010
Alkaline Phosphatase — Cohort B - Baseline Value: Missing00000000
Alanine Aminotransferase — Cohort A - Baseline Value: Low00000000
Alanine Aminotransferase — Cohort B - Baseline Value: Low00000000
Alanine Aminotransferase — Cohort A - Baseline Value: Normal00197070350
Alanine Aminotransferase — Cohort B - Baseline Value: Normal0106702042
Alanine Aminotransferase — Cohort A - Baseline Value: High009014040
Alanine Aminotransferase — Cohort B - Baseline Value: High00000401
Alanine Aminotransferase — Cohort A - Baseline Value: Missing00100010
Alanine Aminotransferase — Cohort B - Baseline Value: Missing00000000
Aspartate Aminotransferase — Cohort A - Baseline Value: Low40000000
Aspartate Aminotransferase — Cohort B - Baseline Value: Low00000000
Aspartate Aminotransferase — Cohort A - Baseline Value: Normal80193040430
Aspartate Aminotransferase — Cohort B - Baseline Value: Normal0006004045
Aspartate Aminotransferase — Cohort A - Baseline Value: High00408010
Aspartate Aminotransferase — Cohort B - Baseline Value: High00010501
Aspartate Aminotransferase — Cohort A - Baseline Value: Missing00200010
Aspartate Aminotransferase — Cohort B - Baseline Value: Missing00000100
Bilirubin — Cohort A - Baseline Value: Low00000000
Bilirubin — Cohort B - Baseline Value: Low00000000
Bilirubin — Cohort A - Baseline Value: Normal101940220330
Bilirubin — Cohort B - Baseline Value: Normal0006902041
Bilirubin — Cohort A - Baseline Value: High00506050
Bilirubin — Cohort B - Baseline Value: High00010202
Bilirubin — Cohort A - Baseline Value: Missing00100010
Bilirubin — Cohort B - Baseline Value: Missing00000000
Calcium — Cohort A - Baseline Value: Low10000000
Calcium — Cohort B - Baseline Value: Low00010000
Calcium — Cohort A - Baseline Value: Normal250219000180
Calcium — Cohort B - Baseline Value: Normal0108100032
Calcium — Cohort A - Baseline Value: High00201000
Calcium — Cohort B - Baseline Value: High00010001
Calcium — Cohort A - Baseline Value: Missing00200000
Calcium — Cohort B - Baseline Value: Missing00000000
Creatinine — Cohort A - Baseline Value: Low10300000
Creatinine — Cohort B - Baseline Value: Low03010000
Creatinine — Cohort A - Baseline Value: Normal10223090150
Creatinine — Cohort B - Baseline Value: Normal0206602032
Creatinine — Cohort A - Baseline Value: High00408000
Creatinine — Cohort B - Baseline Value: High00030601
Creatinine — Cohort A - Baseline Value: Missing00102010
Creatinine — Cohort B - Baseline Value: Missing00010000
Glucose — Cohort A - Baseline Value: Low00000000
Glucose — Cohort B - Baseline Value: Low00000000
Glucose — Cohort A - Baseline Value: Normal00155019090
Glucose — Cohort B - Baseline Value: Normal02025014016
Glucose — Cohort A - Baseline Value: High0020053070
Glucose — Cohort B - Baseline Value: High00013029017
Glucose — Cohort A - Baseline Value: Missing00301010
Glucose — Cohort B - Baseline Value: Missing00010000
Potassium — Cohort A - Baseline Value: Low00000000
Potassium — Cohort B - Baseline Value: Low00010000
Potassium — Cohort A - Baseline Value: Normal50226070180
Potassium — Cohort B - Baseline Value: Normal0207500035
Potassium — Cohort A - Baseline Value: High00700000
Potassium — Cohort B - Baseline Value: High00010101
Potassium — Cohort A - Baseline Value: Missing00400010
Potassium — Cohort B - Baseline Value: Missing00010000
Urea Nitrogen — Cohort A - Baseline Value: Low20000000
Urea Nitrogen — Cohort B - Baseline Value: Low00000000
Urea Nitrogen — Cohort A - Baseline Value: Normal10222080120
Urea Nitrogen — Cohort B - Baseline Value: Normal0005408025
Urea Nitrogen — Cohort A - Baseline Value: High001107020
Urea Nitrogen — Cohort B - Baseline Value: High0004016010
Urea Nitrogen — Cohort A - Baseline Value: Missing00200010
Urea Nitrogen — Cohort B - Baseline Value: Missing00000000
SecondaryChanges From Baseline in Electrocardiogram (ECG) Parameters (Safety Outcome Measure)
Time frame:
Changes in ECG pre-drug dosing and within 1-2 hours post-dosing
Reported as:
Count of participants · Participants
Changes From Baseline in Electrocardiogram (ECG) Parameters (Safety Outcome Measure)
ParticipantsHigh Risk Prostate Cancer (Cohort A) - Baseline ECGHigh Risk Prostate Cancer (Cohort A) - Post-dosing ECGRecurrent or Metastatic Prostate Cancer (Cohort B) - Baseline ECGRecurrent or Metastatic Prostate Cancer (Cohort B) - Post-dosing ECG
Normal ECG Evaluation1591555551
Abnormal ECG Evaluation1011095964
SecondaryMean Changes From Baseline in Blood Pressure Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Time frame:
Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
Reported as:
Mean · mm Hg
Mean Changes From Baseline in Blood Pressure Post 18F-DCFPyL Dosing (Safety Outcome Measure)
mm HgHigh Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)
Systolic Blood Pressure: Baseline (Actual)133.7 ± 15.99133.6 ± 19.00
Systolic Blood Pressure: Post-dosing (Actual)133.7 ± 16.57132.1 ± 19.11
Systolic Blood Pressure: Change from Baseline0.1 ± 12.30-1.3 ± 11.57
Diastolic Blood Pressure: Baseline (Actual)79.3 ± 8.6277.2 ± 10.16
Diastolic Blood Pressure: Post-dosing (Actual)78.5 ± 9.1276.4 ± 9.02
Diastolic Blood Pressure: Change from Baseline-0.7 ± 7.04-0.7 ± 8.18
SecondaryMean Change From Baseline in Heart Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Time frame:
Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
Reported as:
Mean · beats per minute
Mean Change From Baseline in Heart Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
beats per minuteHigh Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)
Heart Rate: Baseline (Actual)70.7 ± 12.0371.3 ± 12.94
Heart Rate: Post-dosing (Actual)66.4 ± 10.9867.0 ± 11.23
Heart Rate: Change from Baseline-4.4 ± 6.88-4.6 ± 6.53
SecondaryMean Change From Baseline in Respiration Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Time frame:
Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
Reported as:
Mean · breaths per minute
Mean Change From Baseline in Respiration Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
breaths per minuteHigh Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)
Respiration Rate: Baseline (Actual)16.7 ± 3.3317.3 ± 2.16
Respiration Rate: Post-dosing (Actual)16.6 ± 3.3217.3 ± 2.28
Respiration Rate: Change from Baseline-0.1 ± 2.030.0 ± 2.00
SecondaryMean Change From Baseline in Temperature Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Time frame:
Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
Reported as:
Mean · degrees Celsius
Mean Change From Baseline in Temperature Post 18F-DCFPyL Dosing (Safety Outcome Measure)
degrees CelsiusHigh Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)
Temperature: Baseline (Actual)36.58 ± 0.43336.56 ± 0.338
Temperature: Post-dosing (Actual)36.50 ± 0.47936.59 ± 0.309
Temperature: Change from Baseline-0.08 ± 0.4960.03 ± 0.265
SecondarySensitivity of 18F-DCFPyL PET/CT Imaging to Detect Prostate Cancer Within Sites of Metastasis or Local Recurrence Relative to Histopathology in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)

Sensitivity (True Positive rate) measures the proportion of positives that are correctly identified (i.e., the proportion of those who have some condition (affected) who are correctly identified as having the condition).

Time frame:
Within 28 days of 18F-DCFPyL PET/CT imaging, conventional image-guided biopsy occurred.
Reported as:
Number · percentage of participants
Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Prostate Cancer Within Sites of Metastasis or Local Recurrence Relative to Histopathology in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)
percentage of participantsRecurrent or Metastatic Prostate Cancer (Cohort B)
Central Reader 198.6 (91.60 to 100.00)
Central Reader 295.8 (87.81 to 99.04)
Central Reader 392.9 (83.98 to 97.28)
SecondaryComparison of Detection Rates for Lesion Counts By Location and Overall Between 18F-DCFPyL PET/CT and Conventional Imaging

The number of lesions detected on imaging categorized as bone, visceral/soft tissue, lymph nodes, and the prostate gland will be determined by each of the central imaging core lab independent readers. The sum of lesions per participant per tissue type and overall will be computed for each participant based on each reader's lesion count. This will be calculated from the 18F-DCFPyL PET/CT scan results as well as the conventional imaging results.

Time frame:
Within 1-2 hours of 18F-DCFPyL dosing, a whole body PET/CT scan will be taken
Reported as:
Count of participants · Participants
Comparison of Detection Rates for Lesion Counts By Location and Overall Between 18F-DCFPyL PET/CT and Conventional Imaging
ParticipantsCohort A - Conventional ImagingCohort A - 18F-DCFPyL PET/CT: Reader 1Cohort A - 18F-DCFPyL PET/CT: Reader 2Cohort A - 18F-DCFPyL PET/CT: Reader 3Cohort B - Conventional ImagingCohort B - 18F-DCFPyL PET/CT: Reader 1Cohort B - 18F-DCFPyL PET/CT: Reader 2Cohort B - 18F-DCFPyL PET/CT: Reader 3
Tissue Site: Bone — Number of Lesions: 023923424723737222823
Tissue Site: Bone — Number of Lesions: 1-291741320212422
Tissue Site: Bone — Number of Lesions: 3-40112810410
Tissue Site: Bone — Number of Lesions: 5-620001352
Tissue Site: Bone — Number of Lesions: >6100026373236
Tissue Site: Visceral/Soft Tissue — Number of Lesions: 023324124924072717364
Tissue Site: Visceral/Soft Tissue — Number of Lesions: 1-2161131213151420
Tissue Site: Visceral/Soft Tissue — Number of Lesions: 3-410003214
Tissue Site: Visceral/Soft Tissue — Number of Lesions: 5-600002120
Tissue Site: Visceral/Soft Tissue — Number of Lesions: >610002435
Tissue Site: Lymph Nodes — Number of Lesions: 015721622621837383738
Tissue Site: Lymph Nodes — Number of Lesions: 1-23928192518111610
Tissue Site: Lymph Nodes — Number of Lesions: 3-410545871310
Tissue Site: Lymph Nodes — Number of Lesions: 5-6163337848
Tissue Site: Lymph Nodes — Number of Lesions: >62900122292327
Tissue Site: Prostate Gland — Number of Lesions: 0162551479646963
Tissue Site: Prostate Gland — Number of Lesions: 1-28819920920412202230
Tissue Site: Prostate Gland — Number of Lesions: 3-403833310610
Tissue Site: Prostate Gland — Number of Lesions: 5-6010430100
Tissue Site: Prostate Gland — Number of Lesions: >600100210
Tissue Site: All — Number of Lesions: 01093514143117
Tissue Site: All — Number of Lesions: 1-27517419617511151714
Tissue Site: All — Number of Lesions: 3-41655384781098
Tissue Site: All — Number of Lesions: 5-61791011991011
Tissue Site: All — Number of Lesions: >635113550564653
Statistical analysis
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 1 · Fisher Exact · p = 0.1097
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 2 · Fisher Exact · p = 0.1087
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 3 · Fisher Exact · p = 0.1949
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 1 · Fisher Exact · p = 0.1315
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 2 · Fisher Exact · p = 0.1977
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 3 · Fisher Exact · p = 0.2149
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 1 · Fisher Exact · p = 0.2582
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 2 · Fisher Exact · p = 0.0009
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 3 · Fisher Exact · p = 0.3588
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 1 · Fisher Exact · p = 0.8791
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 2 · Fisher Exact · p = 0.9457
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 3 · Fisher Exact · p = 0.2705
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 1 · Chi-squared · p = <0.0001
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 2 · Chi-squared · p = <0.0001
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 3 · Chi-squared · p = <0.0001
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 1 · Chi-squared · p = 0.5933
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 2 · Chi-squared · p = 0.7094
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 3 · Chi-squared · p = 0.5424
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 1 · Chi-squared · p = <0.0001
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 2 · Fisher Exact · p = <0.0001
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 3 · Fisher Exact · p = <0.0001
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 1 · Fisher Exact · p = 0.0038
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 2 · Fisher Exact · p = 0.0647
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 3 · Chi-squared · p = 0.0021
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 1 · Chi-squared · p = <0.0001
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 2 · Chi-squared · p = <0.0001
  • Cohort A - Conventional Imaging vs Cohort A - 18F-DCFPyL PET/CT: Reader 3 · Chi-squared · p = <0.0001
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 1 · Chi-squared · p = 0.0815
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 2 · Chi-squared · p = 0.7507
  • Cohort B - Conventional Imaging vs Cohort B - 18F-DCFPyL PET/CT: Reader 3 · Chi-squared · p = 0.5620
SecondaryPositive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)

Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.

Time frame:
Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Reported as:
Number · percentage of participants
Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)
percentage of participantsHigh Risk Prostate Cancer (Cohort A)
Central Reader 1100.0 (98.1 to 100.0)
Central Reader 2100.0 (98.1 to 100.0)
Central Reader 3100.0 (98.1 to 100.0)
SecondaryNegative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)

Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.

Time frame:
Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Reported as:
Number · percentage of participants
Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)
percentage of participantsHigh Risk Prostate Cancer (Cohort A)
Central Reader 10 (NA to NA)
Central Reader 20 (NA to NA)
Central Reader 30 (NA to NA)
SecondaryPositive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)

Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.

Time frame:
Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Reported as:
Number · percentage of participants
Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)
percentage of participantsHigh Risk Prostate Cancer (Cohort A)
Central Reader 186.7 (69.7 to 95.3)
Central Reader 290.5 (69.9 to 98.6)
Central Reader 378.1 (63.8 to 92.5)
SecondaryNegative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)

Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.

Time frame:
Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Reported as:
Number · percentage of participants
Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)
percentage of participantsHigh Risk Prostate Cancer (Cohort A)
Central Reader 183.8 (78.9 to 88.6)
Central Reader 281.4 (76.4 to 86.4)
Central Reader 383.2 (78.2 to 88.1)
SecondaryPositive Predictive Value (PPV) of 18F-DCFPyL PET/CT Imaging to Predict Prostate Cancer Within Sites of Local Recurrence and Other Metastatic Lesions in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)

Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL PET/CT image.

Time frame:
Within 28 days of 18F-DCFPyL PET/CT imaging, conventional image-guided biopsy will occur.
Reported as:
Number · percentage of participants
Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT Imaging to Predict Prostate Cancer Within Sites of Local Recurrence and Other Metastatic Lesions in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)
percentage of participantsRecurrent or Metastatic Prostate Cancer (Cohort B)
Central Reader 181.2 (72.9 to 89.5)
Central Reader 281.9 (73.7 to 90.2)
Central Reader 387.8 (80.4 to 95.3)
SecondaryPeak Plasma Concentration (Cmax) of 18F-DCFPyL in a Subset of Participants
Time frame:
Samples were collected at 0, 5, 15, 30, 60, 120, 240, 360, and 480 minutes after administration of 18F-DCFPyL.
Reported as:
Mean · µCi/mL
Peak Plasma Concentration (Cmax) of 18F-DCFPyL in a Subset of Participants
µCi/mLPharmacokinetic Subset of High Risk Prostate Cancer Participants (Cohort A)
Peak Plasma Concentration (Cmax) of 18F-DCFPyL in a Subset of Participants0.43 ± 0.088
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of 18F-DCFPyL in a Subset of Participants
Time frame:
Samples were collected at 0, 5, 15, 30, 60, 120, 240, 360, and 480 minutes after administration of 18F-DCFPyL.
Reported as:
Mean · h*μCi/ml
Area Under the Plasma Concentration Versus Time Curve (AUC) of 18F-DCFPyL in a Subset of Participants
h*μCi/mlPharmacokinetic Subset of High Risk Prostate Cancer Participants (Cohort A)
Area Under the Plasma Concentration Versus Time Curve (AUC) of 18F-DCFPyL in a Subset of Participants0.82 ± 0.143

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were collected from Day 1 after 18F-DCFPyL administration through the day prior to prostatectomy, lymphadenectomy or a change in planned protocol procedure (Cohort A); if a participant did not have a procedure, TEAEs were collected for up to 10 days after 18F-DCFPyL administration. For participants in Cohort B, TEAEs were collected from Day 1 after 18F-DCFPyL administration through 28 days after biopsy.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Risk Prostate Cancer (Cohort A)0/268 (0%)1/268 (0.4%)26/268 (9.7%)
Recurrent or Metastatic Prostate Cancer (Cohort B)0/117 (0%)6/117 (5.1%)1/117 (0.9%)
Most frequent serious events
Most frequent serious events
EventHigh Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)
coronary artery diseaseCardiac disorders1/2681/117
atrial fibrillationCardiac disorders0/2681/117
Lower gastrointestinal haemmorhageGastrointestinal disorders0/2681/117
pyelonephritis, acuteInfections and infestations0/2681/117
hyperkalaemiaMetabolism and nutrition disorders0/2681/117
spinal cord compressionNervous system disorders0/2681/117
Most frequent other events
Most frequent other events
EventHigh Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)
dysgeusiaNervous system disorders9/2681/117
headacheNervous system disorders9/2680/117
fatigueGeneral disorders5/2680/117
diarrheaGastrointestinal disorders3/2680/117

Baseline characteristics

Safety population; total number of patients who received 18F-DCFPyL injection.

Age, Continuous
Age, Continuous(years)High Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)Total
Median65 (46 to 84)68 (45 to 86)66 (45 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)High Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)Total
Female000
Male268117385
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)High Risk Prostate Cancer (Cohort A)Recurrent or Metastatic Prostate Cancer (Cohort B)Total
Race — White233101334
Race — Black or African American23629
Race — Asian7411
Race — Other235
Race — Unknown or Not Reported336
08

Study locations

10 sites
  • University of California at San Francisco (UCSF) - Mt. Zion Hospital
    San Francisco, California 94143, United States
  • Yale University Department of Radiology and Biomedical Imaging
    New Haven, Connecticut 06520, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • University of Michigan Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Washington University Mallinckrodt Institute of Radilogy
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Jewish General Hospital
    Montreal, Quebec, Canada
  • Centre Hospitalier Universitaire de Quebec (CHUQ)
    Quebec, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jul 2018, 20 months.

Results were first posted in Aug 2021, 3 years 1 month after primary completion. A results delay was requested in Sep 2019.

Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2016
First posted
Dec 5, 2016
StartActual
Nov 2016
Primary completionActual
Jul 2018
CompletionActual
Jul 2018
Results delay requested
Sep 12, 2019
Results first posted
Aug 9, 2021
Last update
Aug 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02981368
Responsible party
Sponsor
First posted
Dec 5, 2016
Start date
Nov 2016
Primary completion
Jul 2018
Completion
Jul 2018
Results posted
Aug 9, 2021
Last update
Aug 9, 2021

Study contacts

Michael J Morris, MD
study chair · Memorial Sloan Kettering Cancer Center
Kenneth J Pienta, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piflufolastat

Start the discussion